(CPRX) Catalyst Pharmaceuticals, Inc. Marketing Mix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(CPRX) Catalyst Pharmaceuticals, Inc. Complete Analysis Pack
See the Bigger Picture
This Catalyst Pharmaceuticals, Inc. 4P's Marketing Mix Analysis summarizes the company’s product, price, place, and promotion strategy and shows how its key marketing choices support positioning and sales; this page includes a real preview/sample of the report so you can evaluate style and content. Purchase the full version to get the complete, ready-to-use analysis.
Product
Firdapse, amifampridine phosphate
Firdapse (amifampridine phosphate) is Catalyst Pharmaceuticals, Inc.'s flagship oral tablet for Lambert-Eaton myasthenic syndrome (LEMS) in the United States. It is the core product in Catalyst Pharmaceuticals, Inc.'s portfolio and supports most of its revenue base, with 2025 full-year product sales reported above $500 million. Its approved niche use and chronic dosing make it a high-value specialty drug.
Ruzurgi for pediatric LEMS
Ruzurgi is Catalyst Pharmaceuticals, Inc.’s pediatric LEMS option for patients aged 6 to 17, extending the same neuromuscular franchise as Firdapse. LEMS is ultra-rare, at about 3 per 1 million people, so the addressable pediatric pool is very small but clinically important. This gives Catalyst a rare-disease bridge from adults to children in the same core therapy area.
Rare neuromuscular disease portfolio
Catalyst Pharmaceuticals, Inc. built its rare neuromuscular disease portfolio for ultra-small patient groups, not mass primary care, with drugs like Firdapse aimed at Lambert-Eaton myasthenic syndrome, a condition affecting about 3 people per 1 million. That orphan-drug focus makes the mix highly specialized and clinically narrow, but it can support premium pricing and tighter prescriber loyalty. In 2024, Catalyst said net product revenue was $421.1 million, showing how a rare-disease portfolio can still scale commercially.
Firdapse label expansion studies
Catalyst Pharmaceuticals, Inc. is studying 3 Firdapse label-expansion paths: MuSK antibody positive myasthenia gravis, spinal muscular atrophy type 3, and hereditary neuropathy with liability to pressure palsies. These programs matter because Firdapse already serves a rare-disease market, so each new label could widen treated patient counts and support longer revenue life. The commercial goal is simple: turn one approved asset into a broader franchise.
- 3 target indications under study
- Rare-disease reach could expand
- New labels can extend sales life
Generic Sabril collaboration
Catalyst Pharmaceuticals, Inc. shares a joint development and commercialization deal with Endo Ventures Limited for a generic Sabril tablet. Sabril (vigabatrin) is tied to epilepsy care, and the pact adds a partnered product path beyond Catalyst Pharmaceuticals, Inc. branded rare-disease assets. It broadens revenue options while keeping development risk shared.
- Joint development and commercialization
- Generic Sabril tablet pathway
- Partnered, lower-risk growth route
- Diversifies beyond rare-disease brands
Catalyst’s rare-disease engine tops $500M as expansion bets build
Product is Catalyst Pharmaceuticals, Inc.’s rare-disease engine: Firdapse targets adult LEMS, while Ruzurgi extends the same neuromuscular franchise to ages 6 to 17. 2025 Firdapse sales topped $500 million, showing strong pricing power in a tiny pool of about 3 LEMS cases per 1 million people. Catalyst Pharmaceuticals, Inc. is also testing 3 label expansions to widen the franchise.
| Item | 2025 data |
|---|---|
| Firdapse sales | >$500M |
| LEMS prevalence | ~3 per 1M |
| Expansion programs | 3 |
What is included in the product
Detailed Word Document
Delivers a concise, company-specific 4P’s analysis of Catalyst Pharmaceuticals, Inc.’s product, pricing, distribution, and promotion strategies.
Editable Excel File
Condenses Catalyst Pharmaceuticals’ 4Ps into a clear, at-a-glance view that quickly relieves marketing analysis pain.
Reference Sources
Provides a concise, traceable list of primary and reputable sources used to validate Catalyst Pharmaceuticals’ market, pricing, and competitive assumptions.
Place
United States market
United States market: Catalyst Pharmaceuticals sells in the U.S. only, so its access, pricing, and payer strategy are built around FDA rules and U.S. specialty pharmacies. Its therapies target rare neuromuscular and neurological diseases, a U.S. patient base often estimated at about 30 million people. That makes domestic reimbursement and distribution the core of Company Name's market reach.
Coral Gables, Florida headquarters
Catalyst Pharmaceuticals, Inc. is headquartered in Coral Gables, Florida, and this site serves as its central operating base. From here, the company runs corporate functions and commercialization planning for its rare-disease portfolio. In 2025, that hub supported U.S. sales growth tied to FIRDAPSE and AGAMREE.
Specialty rare-disease channels
Catalyst Pharmaceuticals, Inc. sells niche rare-disease therapies through specialty channels, not broad retail. That means controlled access via expert prescribers, hubs, and prior-authorization steps, which fits rare conditions with small patient pools. The goal is simple: reach the right neurologists and patients fast, with fewer wasted prescriptions.
Prescriber-led distribution
LEMS is ultra-rare, at about 3 per million people, so Catalyst Pharmaceuticals, Inc. routes FIRDAPSE through prescribers, not broad retail channels. Neurologists and other specialists confirm diagnosis, then guide dosing and monitoring, which helps limit mis-use in a disease that needs tight clinical oversight. This channel fits the small, specialist-treated patient base and supports steady, high-touch care.
- About 3 per million LEMS prevalence
- Specialist diagnosis drives access
- Monitored use lowers selection errors
Access and reimbursement support
Catalyst Pharmaceuticals, Inc. uses access and reimbursement support to move its rare-disease medicines through insurance checks, prior authorizations, and specialty-pharmacy fulfillment. That matters because its model depends on getting treatment started fast for patients who often need coverage approval before first fill. With 2 commercial rare-disease brands, the channel is built for speed, not mass retail.
- Insurance coordination reduces start-up delays
- Fulfillment support improves availability
- Specialty channel fits rare-disease use
Catalyst’s U.S. Access Play for Ultra-Rare Neuromuscular Care
Catalyst Pharmaceuticals, Inc. is a U.S.-only rare-disease company, so its place strategy centers on domestic access, reimbursement, and specialty-pharmacy fulfillment. Its Coral Gables, Florida headquarters coordinates commercialization for FIRDAPSE and AGAMREE. In 2025, this channel fit ultra-rare neuromuscular care, including LEMS at about 3 per million people, where specialist prescribing and payer approval drive first fill speed.
What You See Is What You Get
Catalyst Pharmaceuticals, Inc. Reference Sources
The preview shown here is the actual document you’ll receive instantly after purchase—no surprises.
This is the same ready-made Marketing Mix analysis for Catalyst Pharmaceuticals, Inc. you'll download immediately after checkout, covering Product, Price, Place, and Promotion with actionable insights.
You’re viewing the exact editable, final file included in your purchase—complete and ready to use.
Promotion
Rare-disease physician education
Catalyst Pharmaceuticals, Inc. must educate neuromuscular and oncology specialists on LEMS and related disorders, because LEMS affects about 3 people per 1 million and rare diseases in the U.S. are often defined as fewer than 200,000 patients. In a tiny pool, better physician knowledge can lift diagnosis rates and support Firdapse prescribing.
Patient and caregiver outreach
Patient and caregiver outreach helps Catalyst Pharmaceuticals, Inc. speak directly to the people who spot symptoms first and drive treatment decisions. In rare disease, faster awareness matters: Lambert-Eaton myasthenic syndrome affects only a small patient pool, so education can shorten the path from symptoms to diagnosis. That support also matters after start-up, because long-term therapy works best when patients and caregivers stay engaged and keep dosing on track.
Medical and scientific engagement
Catalyst Pharmaceuticals, Inc. leans on medical and scientific engagement because its rare neuromuscular disease story depends on clinical evidence, not mass-market ads. Congress presentations, peer-reviewed publications, and data sharing help build trust with neurologists and payers. Scientific credibility is a key promotional asset for FIRDAPSE, where treatment decisions hinge on safety and efficacy data.
Partner-based commercialization
Partner-based commercialization gives Catalyst Pharmaceuticals, Inc. access to 2 named licensing and development partners, BioMarin Pharmaceutical Inc. and Endo Ventures Limited. That widens product reach and adds visibility without relying only on Catalyst Pharmaceuticals, Inc.'s own sales force.
Partner networks can also speed promotion by placing brands in established commercial channels. For a rare-disease company, that kind of shared promotion can matter as much as direct selling.
- 2 key partner channels
- Broader market reach
- Partner-led visibility
Reimbursement and access messaging
For Catalyst Pharmaceuticals, Inc., promotion for specialty drugs must do more than build awareness; it should explain prior authorization, formulary status, copay help, and patient support so treatment can start faster and stay on track. This matters because high-friction access steps can delay initiation and hurt persistence. Clear reimbursement messaging turns demand into paid, usable access.
- Explain coverage early
- Reduce prior-authorization friction
- Promote copay and support services
- Help patients stay on therapy
FIRDAPSE Drives Rare LEMS Awareness and Faster Treatment
Catalyst Pharmaceuticals, Inc. promotes FIRDAPSE through neurologist education, congress data, and peer-reviewed evidence, which matters in Lambert-Eaton myasthenic syndrome, a disease that affects about 3 people per 1 million. Patient support and reimbursement guidance also help move patients from diagnosis to treatment faster.
| Promotion driver | Key fact |
|---|---|
| LEMS prevalence | ~3 per 1 million |
| Rare disease line | <200,000 U.S. patients |
| Partner channels | 2 named partners |
Price
Specialty-drug pricing
Catalyst Pharmaceuticals, Inc. prices its rare-disease drugs like FIRDAPSE at a premium because the patient pool is tiny and the clinical benefit is high; the annual list price has been about $375,000 per patient. That kind of pricing is common in orphan drugs, where fixed R&D and regulatory costs are spread over far fewer users. In 2025, the model still depends on low-volume, high-value prescriptions rather than mass-market pricing.
Orphan-drug value model
Catalyst Pharmaceuticals, Inc. builds its price model around orphan drugs, where small patient pools need higher per-patient pricing to fund R&D and sales. FIRDAPSE targets Lambert-Eaton myasthenic syndrome, a U.S. population of about 3,000 patients, which is why rare neuromuscular drugs often carry premium prices. That pricing power is central to Catalyst Pharmaceuticals, Inc.’s economics.
Payer reimbursement focus
Catalyst Pharmaceuticals, Inc. prices its rare-disease drugs around payer access, not just list price, because coverage and prior authorization drive real demand. In 2025, the Medicare Part D out-of-pocket cap is $2,000, so winning reimbursement can sharply cut patient burden and support fills. That makes payer negotiation a core part of the price strategy.
Patient assistance support
Catalyst Pharmaceuticals, Inc. uses patient assistance to blunt the effect of high list prices, especially in rare diseases where about 30 million Americans live with a condition and continuity of therapy matters. These access programs help eligible patients start and stay on treatment, which can protect adherence when out-of-pocket costs would otherwise delay care.
- Helps eligible patients access therapy
- Softens high list-price pressure
- Supports treatment continuity in rare disease
For a specialty drug model, that support can be as important as the price itself.
Partnered economics
Partnered economics shape Catalyst Pharmaceuticals, Inc.'s final price because licensing deals can split gross sales through royalties, profit shares, and launch-cost reimbursements. In rare disease drugs, even a 10%–20% royalty or a $1M+ launch fee can shift list price, rebates, and access terms fast. So pricing is not just demand-driven; it is built around partner take and market access.
- Royalties reduce net price
- Launch costs lift upfront pricing
- Access terms drive final economics
Catalyst’s FIRDAPSE Keeps Its Premium Price in a Tiny Orphan Market
Catalyst Pharmaceuticals, Inc. keeps Price premium because FIRDAPSE serves a tiny orphan market and 2025 access still depends on payer coverage, not volume. The U.S. list price is about $375,000 per patient a year, while Medicare Part D’s $2,000 out-of-pocket cap in 2025 helps keep fills moving. Patient support programs soften the hit and protect adherence.
| Price driver | 2025/2026 data |
|---|---|
| FIRDAPSE list price | ~$375,000/year |
| Medicare Part D OOP cap | $2,000 |
| U.S. LEMS patients | ~3,000 |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.